Berlin Cures' BC 007 Targeting Long COVID Achieves Solid Progress with Over 50% Patient Recruitment in Phase II Trial
- Written by The Bulletin
- Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
- Over 50% of patients in randomized placebo-controlled Phase-II-trial now recruited; no issues regarding safety observed.
